Exelixis Inc Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Exelixis Inc (EXEL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $9.79 per share for the 9-month period ending 2024-09-27, per its 10-Q filed 2024-10-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2024-10-29
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-29 was $10.08.
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-04-01 was $7.51.
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-04-03 was $8.27.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month |
|---|---|---|---|
| 2024-09-27 | $9.79 10-Q · filed 2024-10-29 | ||
| 2024-06-28 | $9.79 10-Q · filed 2024-08-06 | ||
| 2024-03-29 | $10.08 10-Q · filed 2024-04-30 | ||
| 2023-09-29 | $9.45 10-Q · filed 2023-11-01 | ||
| 2023-06-30 | $9.06 10-Q · filed 2023-08-01 | ||
| 2022-09-30 | $8.36 10-Q · filed 2022-11-01 | ||
| 2022-07-01 | $8.36 10-Q · filed 2022-08-09 | ||
| 2022-04-01 | $7.51 10-Q · filed 2022-05-10 | ||
| 2020-10-02 | $9.61 10-Q · filed 2020-11-05 | ||
| 2020-07-03 | $9.74 10-Q · filed 2020-08-06 | ||
| 2020-04-03 | $8.27 10-Q · filed 2020-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |